Senti Biosciences Holdings (SNTI) Retained Earnings (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Retained Earnings of -$358.6 million for Q4 2025, down 20.7% year-over-year from -$452.2 million in Q4 2024, and down 4.21% quarter-over-quarter from -$344.1 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Retained Earnings (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Retained Earnings history runs 5 years deep, the most recent figure standing at -$358.6 million for Q4 2025.
- In Q4 2025, Retained Earnings fell 20.7% year-over-year to -$358.6 million; the TTM figure through Dec 2025 stood at -$358.6 million (down 20.7% YoY), while the FY2025 annual figure was -$358.6 million, down 20.7% from the prior year.
- Retained Earnings for Q4 2025 stood at -$358.6 million, down from -$344.1 million in the prior quarter.
- The five-year high for Retained Earnings was $349.1 million in Q1 2025, with the low at -$358.6 million in Q4 2025.
- The 5-year median for Retained Earnings is -$218.2 million (2023), against an average of -$118.6 million.
- Peak annual rise in Retained Earnings reached 361.12% in 2022, while the deepest fall reached 2122.82% in 2022.
- Senti Biosciences Holdings' Retained Earnings stood at -$115.1 million in 2021, then soared by 361.12% to $300.5 million in 2022, then tumbled by 181.29% to -$244.3 million in 2023, then retreated by 21.61% to -$297.1 million in 2024, then dropped by 20.7% to -$358.6 million in 2025.
- Business Quant data shows SNTI's Retained Earnings at -$358.6 million in Q4 2025, -$344.1 million in Q3 2025, and -$326.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | -375.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -358.60 Mn |
| Sep 30, 2025 | -344.10 Mn |
| Jun 30, 2025 | -326.00 Mn |
| Mar 31, 2025 | 349.10 Mn |
| Dec 31, 2024 | -297.10 Mn |
| Sep 30, 2024 | -296.50 Mn |
| Jun 30, 2024 | -267.70 Mn |
| Mar 31, 2024 | -256.50 Mn |
| Dec 31, 2023 | -244.30 Mn |
| Mar 31, 2023 | -192.01 Mn |
| Dec 31, 2022 | 300.54 Mn |
| Sep 30, 2022 | 295.42 Mn |
| Jun 30, 2022 | -138.40 Mn |
| Dec 31, 2021 | -115.10 Mn |
| Jun 30, 2021 | -6.23 Mn |
| Mar 31, 2021 | 24,425.00 |